Osteoarthritis (OA), the most prevalent form of skeletal disease, represents a leading cause of disability following middle age. OA is characterized by the loss of articular cartilage; however, the details of its etiology and pathogenesis remain unclear. We recently demonstrated a genetic association between the cartilage extracellular matrix protein asporin and OA. Further, we showed that asporin binds to TGF-, a key cytokine in OA pathogenesis, and inhibits TGF--induced chondrogenesis. To date, functional data for asporin have come primarily from mouse cell culture models of developing cartilage, rather than from human articular cartilage cells, where OA occurs. Here we describe mechanisms for asporin function and regulation in human articular cartilage. Asporin blocks chondrogenesis and inhibits TGF-1-induced expression of matrix genes and resulting chondrocyte phenotypes. siRNA-mediated knockdown of asporin increases the expression of cartilage marker genes and TGF-1; in turn, TGF-1 stimulates asporin expression in articular cartilage cells, suggesting that asporin and TGF-1 form a regulatory feedback loop. Asporin inhibits TGF--Smad signaling upstream of TGF-type I receptor (T RI) activation in vivo by co-localizing with TGF-1 on the cell surface and blocking its interaction with the TGF-type II receptor (T RII). Our results provide a basis for elucidating the role of asporin in the molecular pathogenesis of OA.
Osteoarthritis (OA), the most prevalent form of skeletal disease, represents a leading cause of disability following middle age. OA is characterized by the loss of articular cartilage; however, the details of its etiology and pathogenesis remain unclear. We recently demonstrated a genetic association between the cartilage extracellular matrix protein asporin and OA. Further, we showed that asporin binds to TGF-, a key cytokine in OA pathogenesis, and inhibits TGF--induced chondrogenesis. To date, functional data for asporin have come primarily from mouse cell culture models of developing cartilage, rather than from human articular cartilage cells, where OA occurs. Here we describe mechanisms for asporin function and regulation in human articular cartilage. Asporin blocks chondrogenesis and inhibits TGF-1-induced expression of matrix genes and resulting chondrocyte phenotypes. siRNA-mediated knockdown of asporin increases the expression of cartilage marker genes and TGF-1; in turn, TGF-1 stimulates asporin expression in articular cartilage cells, suggesting that asporin and TGF-1 form a regulatory feedback loop. Asporin inhibits TGF--Smad signaling upstream of TGF-type I receptor (T RI) activation in vivo by co-localizing with TGF-1 on the cell surface and blocking its interaction with the TGF-type II receptor (T RII). Our results provide a basis for elucidating the role of asporin in the molecular pathogenesis of OA.
Osteoarthritis (OA 3 ; OMIM 165720) is the most prevalent disease affecting bones and joints, and it represents a leading cause of disability in aging populations. OA is characterized by the loss of articular cartilage, which is comprised of abundant extracellular matrix (ECM) proteins, including proteoglycan and type II collagen (ColII) (1) . Genetic factors have been implicated in the onset and development of OA (2-4) and several susceptibility genes have been reported (5, 6) ; however, the etiology and pathogenesis of OA remain unclear.
Recently, we demonstrated the genetic association of a functional polymorphism in the gene encoding asporin (ASPN) with knee and hip OA in the Japanese population (7) . This association is replicated in knee OA in the Han Chinese population (8) . Asporin is an ECM protein that is abundantly expressed in OA articular cartilage, and its expression increases with progressive cartilage degeneration (7, 9) . Asporin belongs to a family of small leucine-rich proteoglycans (SLRPs), which comprise a major non-collagen component of the ECM (10) . While SLRPs play known roles in biological processes such as skeletal growth, craniofacial structure and collagen fibrillogenesis (11) , the exact role of asporin is not known. Previously, we showed that asporin binds directly to TGF-1 in vitro (7) . Abundant in cartilage ECM, TGF-1 regulates proliferation, differentiation and matrix production of chondrocytes and their progenitor cells (12, 13) . We have also demonstrated that asporin inhibits TGF-1-induced expression of cartilage matrix genes in ATDC5 cells (7) , an in vitro mouse model for chondrogenesis (14, 15) .
These results strongly suggest that asporin acts as a negative regulator of TGF-in cartilage, playing a critical role in the etiology and pathogenesis of OA. However, functional data for asporin have been obtained primarily from mouse cartilage cells rather than from human articular cartilage cells, where OA occurs. In addition, the mechanism by which asporin inhibits TGFfunction, as well as the regulation of asporin in articular cartilage, is yet undetermined.
In the present study, we have investigated the function of asporin in articular cartilage and its mechanism for TGF-inhibition during chondrogenesis. Asporin blocks chondrogenesis at both early and late stages, inhibiting TGF-1-induced gene expression and the resulting chondrocyte phenotypes. Knockdown of asporin by siRNA increases the expression of cartilage marker genes, confirming its physiological role as a negative regulator of chondrogenesis. Asporin inhibits TGF--Smad signaling by co-localizing with TGF-1 on the cell surface and inhibiting its binding to the TGFtype II receptor (T RII). TGF-1 stimulates asporin expression, suggesting that asporin and TGF-1 form a regulatory feedback loop.
EXPERIMENTAL PROCEDURES
Human articular cartilage samples -Articular cartilage samples were obtained during surgery with written informed consent: knee OA cartilage from was obtained from total knee arthroplasties, and normal cartilage was obtained from knee and hip joints. None of the control subjects had a clinical history of joint diseases or showed radiographic signs of OA. For RNA extraction, samples were frozen in liquid nitrogen immediately after resection and stored at -80˚C. For immunohistochemistry, the samples were fixed in 10% buffered formaldehyde and embedded in paraffin. The study protocol was approved by the ethical committees of RIKEN and participating clinical institutions. Cell culture -We purchased normal human articular chondrocytes (NHAC) from Cambrex. To obtain a monolayer culture, NHAC cells were maintained in a standard chondrocyte growth medium (CGM, Cambrex) at 37˚C under 5% CO 2 . To re-differentiate chondrocytes and maintain the differentiated phenotype, we carried out three-dimensional culture using alginate beads (Cambrex) according to the manufacturer's instructions. Unless otherwise noted, we used primary or secondary cells after re-differentiation in alginate bead culture for experiments . To  examine  the  effects  of  asporin  on  TGF-1-induced expression of various genes,  NHAC cells were plated and cultured in a 12-well  plate at a density of 5 x 10 4 cells/well in DMEM/F12 containing 10% FBS until they reached confluence. At this point, the medium was replaced with DMEM/F12 containing 0.2% FBS. After 12 h, cells were treated with recombinant mouse asporin (7) . After 12 h, cells were treated with TGF-1 (40 ng/ml) for 12 h. To examine induction of asporin mRNA by TGF-1, NHAC were cultured in a 12-well plate at a density of 1 x 10 5 cells/well in DMEM/F12 containing 10% FBS until they reached confluence. The medium was then replaced with DMEM/F12 containing 0.2% FBS. After 24 h, cells were treated with TGF-1 (10 ng/ml) for 12 h.
Chondrogenic ATDC5 cells were obtained from the Riken Cell Bank. ATDC5 cells were cultured in DMEM/F-12 containing 5% FBS at 37˚C under 5% CO 2 as described (14, 15) . For induction of chondrogenesis, confluent cells were cultured in medium containing 10 µg/ml insulin, 10 µg/ml transferrin, and 3 x 10 -8 M selenium (ITS; Sigma), and the medium was changed every 2 or 3 days. Real-time quantitative PCR assays -We extracted total RNA from cells using Isogen (Wako Pure Chemical) and purified them using the SV-Total RNA Isolation system (Promega). We synthesized random-primed cDNA using Multiscribe reverse transcriptase (Applied Biosystems). Real-time PCR was carried out on an ABI PRISM 7700 (Applied Biosystems) using QuantiTect SYBR Green PCR (QIAGEN) in accordance with the manufacturer's instructions. High-density oligonucleotide microarray -We carried out high-density oligonucleotide microarray analysis as previously described (7) . Preparation of recombinant mouse asporinRecombinant mouse asporin expressed in Escherichia coli was purified as previously described (7) . The coding sequence for the mouse mature asporin protein was cloned into the pTriEx4 vector (Novagen). Recombinant mouse asporin was also expressed in COS-7 cells and purified from cell lysates using S-protein agarose (Novagen) according to the manufacturer's instructions. Pull-down assay -Pull-down assays to demonstrate direct interactions between asporin and TGF-s were performed as described previously (7) . Briefly, purified recombinant mouse asporin (5 µg) was incubated with 0.1 µg of recombinant TGF-proteins (R&D Systems) for 1 h at 4˚C in 0.3 ml of binding buffer (20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% Triton X-100). We added 12.5 µl of S-protein agarose (Novagen) to the reactions and incubated them for 30 min at 25˚C. The precipitates were washed three times with binding buffer and subjected to SDS-PAGE. The proteins were blotted and visualized with the corresponding antibody. Each blot then was treated with S-protein HRP conjugate (Novagen) to confirm the precipitation of recombinant mouse asporin. Safranin-O staining -After re-differentiation in alginate bead culture, cells were plated on a Lab-Tek II Chamber Slide (Nunc) and cultured in DMEM/F12 containing 5%FBS, ITS in the absence or presence of TGF-1 (40 ng/ml), with or without asporin (20 µg/ml) for 7 days. Cells were washed twice with PBS, fixed with methanol and stained with 0.1% Safranin-O for 5 min at room temperature. Sections of articular cartilage from individuals with OA were stained with Safranin-O-fast green. Safranin-O-positive and negative areas were defined as normal and degenerated areas, respectively. Alcian blue staining and measurement of staining intensity -At day 21 of culture, cells were washed with PBS, fixed with 4% paraformaldehyde for 10 min, stained with alcian blue solution (pH 1.0) (Sigma) overnight at 25˚C. The stained culture plates were rinsed with distilled water and extracted with 6M guanidine-HCl for 2 h at 25˚C. The optical density of the extracted dye was measured at 650 nm with a spectrophotometer. siRNA -We selected three siRNAs (Si1, Si9 and Si16) directed against human asporin using the siRNA design support system available on the Takara Bio Web site (http://www.takara-bio.co.jp). These siRNAs were synthesized and obtained from Takara Bio. Among them, Si9 (target sequences: 5'-UCCCUUCAGGAUUACCAGATT-3' and 5'-UCUGGUAAUCCUGAAGGGATT-3') showed the strongest knockdown effect in NHAC cells. As a control, we used a scrambled siRNA against Si1. We transfected siRNAs into NHAC cells using TransIT TKO (Mirus) and cultured the cells for 24 h in DMEM/F12 containing 0.2% FBS and 10 ng/ml TGF-1 in the presence or absence of TGFneutralizing antibodies (MAB240; R&D Systems). Western blotting -Cells were plated at 5 x 10 4 cells/well in 12-well plastic tissue culture plates in medium containing ITS. After 24h, the medium was changed to DMEM/F-12 containing 0.2% FBS and ITS. 16h later, cells were treated with 10 ng/ml TGF-1 for 5 min at 37˚C. Recombinant mouse asporin was added 1 h prior to TGF-1 treatment. After incubation, the cells were lysed using the M-PER protein extraction kit (Pierce) containing a protease inhibitor cocktail (Roche). Proteins in the cell lysate were separated by electrophoresis on SDS-polyacrylamide gels and transferred onto nitrocellulose membranes (Amersham Biosciences). The membranes were incubated in 5% nonfat dry milk in 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.05% Tween-20 to block non-specific binding. Primary antibodies against phosphorylated Smad2 (Cell Signaling) and Smad2 (Invitrogen) were used at a 1:1,000 dilution. Membranes were then incubated in horseradish peroxidase-conjugated anti-rabbit IgG at a 1:3,000 dilution (Cell Signaling). Construction of plasmids -The SBE4-Luc plasmid was constructed as previously described (16) . We cloned a cDNA encoding human T RI (ALK-5) into the pcDNA3.1 vector (Invitrogen), and a constitutively active mutant T RI (T204D) was engineered by PCR using mutagenic primers, as previously described (17) . Each construct was verified by DNA sequencing (Model 3700; Applied Biosystems). Luciferase assay -Cells were plated at a density of 2.5 x 10 4 cells/well in 24-well plastic tissue culture plates and cultured in DMEM/F-12 containing 5% FBS. Cells were transiently transfected with the reporter SBE4-Luc plasmid and the pRL-TK vector (Promega) as an internal control, using FuGENE6 (Roche) as a transfection reagent. After 24 h, cells were transferred to medium containing 0.2% FBS with or without recombinant mouse asporin and, after 1 h, treated with TGF-1 for 24 h. To demonstrate the effect of asporin on ligand (extracellular TGF-)-independent Smad activation, cells were transiently transfected with SBE4-Luc and pcDNA3.1 containing the constitutively active mutant T RI (T204D) construct (17) . After 24 h, cells were transferred to medium containing 0.2% FBS with or without recombinant mouse asporin and cultured for 24h. Luciferase activity was measured using the PG-DUAL-SP Reporter Assay System (Toyo Ink). Affinity cross-linking -Recombinant human TGF-1 was iodinated using the Chloramine-T method as described (18) . ATDC5 cells were incubated for 3 h at 4˚C with 10 ng/ml 125 I-TGF-1 in binding buffer (phosphate-buffered saline containing 1 mM CaCl 2 , 0.5 mM MgCl 2 , and 1 mg/ml bovine serum albumin). After incubation, the cells were washed with the same binding buffer without bovine serum albumin, and cross-linking was performed in buffer containing 0.27 mM disuccinimidyl suberate (DSS, Pierce) for 15 min at 4˚C. The cells were then washed once with 10 mM Tris-HCl buffer, pH 7.4, containing 1 mM EDTA, 10% glycerol, and protease inhibitor cocktail (Roche). Cells were scraped, centrifuged and resuspended in solubilization buffer (1% Triton X-100, 1% deoxycholate, 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, and protease inhibitor cocktail), followed by incubation on ice for 30 min. Cell lysates were mixed with an equal amount of SDS-sample buffer (100 mM Tris-HCl, pH 6.8, 0.01% bromophenol blue, 36% glycerol, 4% SDS) containing 10 mM dithiothreitol and analyzed on 7% SDS-PAGE. The gels were dried and subjected to analysis using a BAS-2500 imaging analyzer (Fuji film). Immunohistochemistry -Immunohistochemistry was carried out as previously described (19) . Sections were stained with anti-asporin antibody (2229-B01; 1 µg/ml) or anti-TGF-1 antibody (sc-146, Santa Cruz Biotechnology; 1 µg/ml) at 4˚C for 18 h. Immunofluorescence microscopy -Cells were fixed for 15 min in 4% paraformaldehyde at 25˚C and blocked with 10% normal goat serum (Invitrogen) in PBS for 1 h at 25˚C. The fixed cells were incubated with anti-asporin antibody (2210-B02; 3 µg/ml) and subsequently incubated with Alexa Fluor 546 goat-anti rabbit IgG (H+L) (Invitrogen) for 30 min at 25˚C. After staining, the cells were mounted in VECTASHIELD mounting medium with DAPI (Vector Laboratories) and examined with an Olympus IX70 Fluoview confocal microscope (Olympus). For double staining with TGF-1, a Human TGF-1 Biotinylated Fluorokine Kit (R&D Systems) was used according to the manufacturer's protocol with a slight modification: Prior to fixation, cells were incubated with biotinylated TGF-1 for 1 h at 4˚C. Biotinylated TGF-1 bound to cells was visualized with avidin-FITC.
RESULTS

TGF-1 is predominant among TGF-isoforms
in human articular cartilage -Three TGFisoforms with similar functions exist in mammals (TGF-1, 2 and 3), and all are expressed in ATDC5 cells (20) . Upon finding that asporin binds to TGF-2 and TGF-3 as well as TGF-1 (Fig. 1) , we evaluated the significance of each isoform in OA. Using microarray and real-time PCR, we examined the expression of all isoforms in cartilage samples from normal subjects and OA patients, as well as in normal human articular chondrocyte (NHAC; Cambrex). Among the isoforms, TGF-1 was most abundantly expressed in OA and non-OA articular cartilage and in NHAC, and its expression levels were higher in OA cartilage than in non-OA samples (Fig. 2) . Increased expression in of TGF-3 in the microarray analysis was not replicated in the real-time PCR analysis. These results indicate that TGF-1 is the most important of the three isoforms in human articular cartilage and OA. Effect of asporin on cartilage differentiation and TGF-1-induced expression of cartilage matrix genes in articular cartilage -We previously demonstrated that asporin overexpression inhibits early chondrogenic differentiation in ATDC5 cells (7) . To confirm the influence of asporin in this model, we measured the expression of chondrogenic differentiation marker genes (aggrecan, ColII and type X collagen [ColX] ) in the presence of recombinant mouse asporin. Asporin decreased the expression of marker genes in a dose-dependent manner (Fig. 3A-C) . Asporin also inhibited glycosaminoglycan accumulation, measured at day 21 of culture ( Fig.  3D) . To verify that the TGF-binding (Fig. 1A) and chondrogenesis inhibitory activities (Fig.  3A-D) of recombinant asporin prepared from E. coli were comparable to native asporin, we examined these activities using recombinant asporin produced using a eukaryotic expression system (COS-7). As shown in Fig. 1B, C, 3E , and F, the activities were similar.
ATDC5 is an excellent model for chondrogenesis; sequential steps of chondrocyte differentiation are reflected in ATDC5 cells by increased expression of the chondrogenic differentiation marker genes ColII and ColX in the presence of insulin (14, 15) ; however, it most precisely represents growing cartilage in the mouse (21) rather than human articular cartilage, where OA occurs. To clarify asporin function in human articular cartilage, we examined its effect on TGF-1-induced expression of ColII and aggrecan mRNA in NHAC cells. Recombinant mouse asporin inhibited TGF-1-induced expression of cartilage matrix genes in a dose-dependent manner (Fig. 4A and B) , supporting the observations made in the ATDC5 model. Asporin inhibits re-differentiation of NHAC cells induced by TGF-1 -Articular cartilage chondrocytes lose their characteristic phenotype (de-differentiate) during passage. TGF-induces the restoration of the cartilage phenotype (re-differentiation), as evidenced by increased proteoglycan synthesis and a change from a fibroblastic to a chondrocytic (polygonal or spherical) cell shape (22) (23) (24) . We examined the effect of asporin on TGF-1-induced changes in the cartilage phenotype of NHAC. Most TGF-1-stimulated cells exhibited a spherical shape typical of chondrocytic cells, with areas of clustered cells staining strongly with Safranin-O, a marker for proteoglycan synthesis (Fig. 4D) . Control (non-stimulated) cells, however, showed a fibroblastic morphology with no Safranin-O staining (Fig. 4C) . Addition of asporin changed the morphology of TGF-1-stimulated cells to a fibroblastic phenotype and reduced Safranin-O staining (Fig. 4E) . Together, these results indicate that asporin reverses the TGF-1-induced chondrocyte phenotype in human articular chondrocytes. Endogenous asporin suppresses expression of cartilage matrix genes -To clarify the physiological role of asporin in human articular chondrocytes, we decreased endogenous asporin levels in NHAC cells via siRNA and measured expression of cartilage marker genes. Knockdown of asporin significantly increased ColII and aggrecan mRNA expression (Fig. 5A-C) , as well as TGF-1 (Fig. 5D ), indicating that asporin negatively regulates cartilage matrix gene expression in articular cartilage under physiologic conditions. The siRNA-induced increase in ColII and aggrecan mRNA expression was inhibited by TGF-neutralizing antibodies ( Fig. 5B and C) , suggesting that increased in the matrix gene expression is due to increased available TGF-. Asporin inhibits TGF-1-Smad signaling -We further investigated the influence of asporin on chondrogenesis by examining its effects on TGF-1-Smad signaling. In ATDC5 cells, recombinant asporin inhibited TGF-1-induced phosphorylation of Smad2 in a dose-dependent manner (Fig. 6A) . Next, we measured the effect of asporin on TGF-1-induced Smad3/4-specific reporter activity using a luciferase construct containing four tandem repeats of Smad binding elements (SBE4-Luc) (16) . Asporin significantly reduced TGF-1-induced SBE4-Luc activity (Fig.  6B) . Confirmation of these inhibitory effects in NHAC cells (Fig. 6C and D) indicates that asporin negatively regulates TGF-1-Smad signaling in articular cartilage.
Smad signaling is modulated not only by T RI kinase, but also by various molecules such as inhibitory Smads (I-Smads), ERK MAP kinase, and PI3K/Akt pathways (25) . To characterize the potential influence of asporin on Smad signaling, we used a constitutively active T RI (T204D), which activates Smad in the absence of TGF- (17) .
Asporin did not inhibit T RI-induced transcriptional activation of Smad (Fig. 6E) , suggesting that it works upstream of T RI activation and exerts no downstream effect following Smad activation. This result is consistent with our previous finding that asporin is an ECM protein that interacts with TGF-1 (7). Therefore, we examined the effect of asporin on TGF-1 binding to cell surface receptors in vivo. Cells were incubated with 125 I-labelled TGF-1 in the presence or absence of asporin, then 125 I-TGF-1-receptor complexes were cross-linked and analyzed by SDS-PAGE. Addition of asporin reduced TGF-1 binding to T RI and T RII in a dose-dependent manner ( Fig.  6F and G) . Together, these findings suggest that asporin regulates TGF-1 signaling by preventing interaction between TGF-and its receptor on the cell surface.
Asporin colocalizes with TGF-1 in vivoPreviously we demonstrated that asporin and TGF-1 directly interact in vitro.
To investigate the interaction in vivo, we examined the localization of asporin in articular cartilage from individuals with OA using immunohistochemistry. Asporin appeared in clustered chondrocytes in areas of severe degeneration, which were revealed by staining with Safranin-O, but was barely detectable in normal areas (Fig. 7A) . TGF-1 showed a similar localization pattern, suggesting that asporin and TGF-1 are upregulated and colocalize in chondrocytes within OA lesions of human articular cartilage. We further investigated the localization of asporin and TGF-1 in NHAC cells using immunocytochemistry. Biotinylated TGF-1 and endogenous asporin both were detected on clustered cells (Fig. 7B) . Asporin staining was clearly detected on cells not permeabilized with Triton X-100, but was barely visible in permeabilized cells (Fig. 7C) . In contrast, staining of Smad2, a marker for intracellular proteins, was stronger in permeabilized cells. These observations indicate that asporin localizes to the cell surface and, when there, interacts with TGF-1. Expression of asporin mRNA is induced by TGF-1 -Expression of some negative regulators of TGF-signaling, such as Smad7, is induced by TGF-1 itself, forming a functional feedback loop (26) . We therefore investigated whether TGF-1 influences asporin expression. In NHAC cells, asporin mRNA was induced by addition of TGF-1 (Fig. 8A ) as early as 6 h after stimulation. If asporin induction likely occurs through TGF-, then exogenous asporin should inhibit TGF-1-induction of asporin. We confirmed this prediction in NHAC cells treated with asporin, observing inhibition of TGF-1-induced expression of endogenous asporin in a dose-dependent manner ( Fig. 8B and C) .
DISCUSSION
The SLRP family consists of 13 known members that can be divided into three distinct sub-families based on their genomic organization, structure and amino acid sequence similarity (10) . Asporin belongs to the group of class I SLRPs that also includes decorin and biglycan (9, 27) ; unlike other family members, however, asporin lacks a glycosaminoglycan attachment site and hence is not a proteoglycan. Also unique to asporin is a polymorphic aspartic acid (D) repeat in the N-terminal region, which ranges in length from 8 to 19 residues (7, 8, 28) . This repeat shows a significant genetic association with knee and hip OA, with the D14 allele being over-represented in OA (7, 8) . Our previous study using mouse chondrocytes demonstrated that asporin is a negative regulator of TGF-function (7). This study confirms the inhibitory effect of asporin on TGF-function during chondrogenesis in human articular cartilage chondrocytes.
Several SLRPs, including decorin, biglycan and fibromodulin, have been shown to bind TGF-proteins (29) (30) (31) . Decorin inhibits TGF-function; in vivo administration of decorin prevents fibrosis caused by overexpression of TGF-in experimental animal models (32, 33) . Two mechanisms for decorin inhibition of TGFhave been reported, although neither was demonstrated in cartilage. In macrophages, decorin reverses the inhibitory effect of TGF-by binding to it and preventing its interaction with the cell surface (34) . It is likely that decorin blocks interaction of TGF-with its cell surface receptor(s), but this has not been confirmed. Inhibition of TGF-by decorin also can occur through regulation of intracellular Smad and other signaling crosstalk (35) . In human mesangial cells, decorin inhibits TGF--induced expression of plasminogen activator inhibitor-1 via activation of the Ca 2+ /calmodulin-dependent protein kinase II, which results in phosphorylation of Smad2 at Ser204, an important negative regulatory site. Our data argue against such crosstalk in asporin-mediated TGFinhibition.
We previously showed that asporin directly binds to the mature form of TGF-and inhibits its biological effects on mouse chondrocytes (7). Here we show that asporin colocalizes with TGFin the human articular cartilage extracellular space, inhibiting TGF-signaling upstream of T RI. Asporin shows no inhibitory effect on signaling downstream of T RI, however. Through cross-linking experiments, we have demonstrated that asporin inhibits TGF-1 binding to T RII. These lines of evidence indicate that asporin in the ECM inhibits TGFsignaling directly at the receptor level. A serum glycoprotein, fetuin, also inhibits TGF-activity by competing with TGF-for binding to T RII (36) . Fetuin and T RII show homology in the TGF-receptor II homology 1 (TRH1) domain, an 18-19-amino acid sequence that interacts with TGF-. Fetuin binds directly to TGF-1 via this domain and inhibits binding of TGF-1 to the extracellular domain of T RII. Cystatin C, which like fetuin belongs to the type 3 cystatin family, also inhibits TGF-signaling by preventing the binding of TGF-to T RII, although physical binding of cystatin C to TGF-has not been proven (37) . We think, however, that such a mechanism is unlikely in asporin because it lacks a TRH1 domain. Further study is necessary to determine the precise inhibitory mechanism of the binding of TGF-to T RII by asporin.
In summary, we have created a more detailed picture of asporin function and regulation, both in normal cell physiology and in OA. Asporin negatively regulates chondrogenesis in articular cartilage by blocking the TGF--receptor interaction on the cell surface and inhibiting the canonical TGF--Smad signal. Further, asporin and TGF-1 form a functional feedback loop in human articular cartilage. TGF-signaling is critical for maintaining healthy articular cartilage, and suppression of TGF-signaling in chondrocytes leads to OA (38) (39) (40) . Our studies suggest that asporin is a critical regulator of TGF-in articular cartilage and thus plays an essential role in cartilage homeostasis and OA pathogenesis. Inhibition of asporin, then, should enhance cartilage regeneration by increasing TGF-activity. More detailed study of the physical interface between the two molecules will be key to developing innovative treatments for OA, as it represents a promising target for agents that control and modify the asporin/TGF-system. 
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